#Epigenetics And Epitranscriptomics

[owlservice]

Last night I was rereading my notes on nervous system changes during hibernation, and came across RNA motif binding protein 3 (RMBP3), which is posited as the potential master switch allowing hibernation to occur. Long story short, I found out about epitranscriptomics. I knew about epigenetics, and I knew about post translational modifications, and I knew about mRNA splicing variants, but I didn't know about post transcriptional modifications of the mRNA transcript at the level of the nucleotide. Did you guys know about this... It was never mentioned in my degree

[medicomunicare]

It's a supplement aFTOr all: how tocopherol acetate VESsels for anticancer defences

Epigenetics and epitranscriptomics play a crucial role in modifying gene expression without altering gene sequence. N6-methyladenosine (m6A) is one such mechanism, where methyl groups are added to the N6 position of adenosine on RNA. Adding these methyl groups enhances RNA stability; however, their removal by enzymes can promote development of tumors. High levels of fat mass and…

[healthcaremarketanalysis]

Exploring the Epigenetics Market: Trends, Growth, and Future Prospects

The epigenetics market is gaining significant momentum in the life sciences and healthcare sectors. This field, which studies heritable changes in gene expression without altering the DNA sequence, is instrumental in understanding complex biological processes and diseases. From drug discovery to personalized medicine, epigenetics offers transformative potential, making it a crucial area of research and development.

In this blog, we’ll delve into the key trends, market dynamics, applications, and growth drivers shaping the epigenetics market.

Understanding Epigenetics

Epigenetics refers to modifications on DNA or associated proteins that regulate gene activity without changing the underlying sequence. These modifications include:

DNA Methylation – The addition of methyl groups to DNA, often silencing gene expression.

Histone Modification – Changes in proteins around which DNA is wrapped, affecting gene accessibility.

Non-Coding RNAs – Molecules that influence gene expression post-transcriptionally.

Epigenetic mechanisms are reversible, making them attractive therapeutic targets for diseases like cancer, neurodegenerative disorders, and autoimmune conditions.

Market Overview

Market Size and Growth

The global epigenetics market was valued at approximately $1.4 billion in 2023 and is projected to grow at a CAGR of 15-18% over the next decade. This growth is driven by increasing research in gene therapy, rising cancer prevalence, and advancements in epigenetic technologies.

Key Market Segments

The market can be categorized into the following:

Products:

Reagents

Kits

Instruments (e.g., sequencers, microarrays)

Software

Applications:

Oncology

Developmental Biology

Metabolic Disorders

Neurology

End Users:

Academic Research Institutions

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Drivers of Market Growth

1. Rising Prevalence of Cancer

Cancer is a leading application area for epigenetic research. Abnormal epigenetic modifications are closely linked to tumorigenesis. Epigenetic therapies, such as DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors, are showing promising results in cancer treatment.

2. Advances in Epigenomics Technologies

The development of high-throughput sequencing and microarray platforms has made it possible to study epigenetic changes on a genome-wide scale. Tools like CRISPR-based epigenome editing are expanding research possibilities.

3. Increasing Focus on Personalized Medicine

Epigenetics plays a critical role in tailoring therapies based on individual genetic and epigenetic profiles. This approach is gaining traction, especially in oncology and chronic disease management.

4. Government and Private Funding

Governments worldwide are investing heavily in genomics and epigenetics research. For instance, the National Institutes of Health (NIH) in the U.S. allocates substantial grants for epigenetics projects. Private investments and collaborations are also fueling market growth.

Challenges in the Epigenetics Market

1. High Costs of Research and Equipment

Epigenetic research requires advanced instruments and reagents, which can be cost-prohibitive for smaller organizations.

2. Complexity of Epigenetic Mechanisms

The dynamic and reversible nature of epigenetic changes makes it challenging to pinpoint causal relationships between modifications and diseases.

3. Regulatory and Ethical Issues

Using epigenetic data in personalized medicine raises concerns about data privacy and ethical implications.

Emerging Trends in the Epigenetics Market

1. Integration of AI and Big Data

Artificial Intelligence (AI) and machine learning algorithms are being used to analyze complex epigenomic datasets, accelerating discoveries.

2. Focus on Epitranscriptomics

This subfield studies modifications in RNA rather than DNA, opening new avenues for understanding gene regulation.

3. Development of Epigenetic Biomarkers

Biomarkers are being developed for early diagnosis, prognosis, and treatment monitoring in diseases like cancer, Alzheimer’s, and diabetes.

4. Expansion of Non-Oncology Applications

While oncology dominates the market, epigenetics is increasingly applied in neurodegenerative diseases, cardiovascular disorders, and metabolic syndromes.

Competitive Landscape

Key players in the epigenetics market include:

Illumina, Inc. – Leading in sequencing technologies.

Thermo Fisher Scientific, Inc. – Offering comprehensive epigenetics solutions.

Abcam plc – Specializing in antibodies and kits for epigenetic research.

Qiagen – Providing tools for epigenomic studies.

Merck KGaA – Known for its advanced reagents and inhibitors.

Collaborations, acquisitions, and product launches are common strategies adopted by these players to strengthen their market position.

Applications of Epigenetics

1. Cancer Research and Therapy

Epigenetic drugs are used to reprogram cancer cells, making them more susceptible to traditional therapies.

2. Developmental Biology

Epigenetics helps unravel how environmental factors influence gene expression during development.

3. Neurology

Research in conditions like Alzheimer’s and Parkinson’s diseases focuses on epigenetic mechanisms underlying neuronal dysfunction.

4. Agriculture and Veterinary Science

Epigenetic studies in plants and animals aim to enhance productivity and disease resistance.

Future Prospects

The future of the epigenetics market is promising, with continued advancements in technology and an expanding scope of applications. Personalized medicine and precision oncology are expected to be major growth areas. Moreover, the rise of epigenome editing tools and novel biomarkers will drive innovation in diagnostics and therapeutics.

Conclusion

The epigenetics market represents a dynamic and rapidly evolving field with immense potential to transform healthcare and research. As we continue to uncover the intricacies of the epigenome, the applications of this science will expand, offering solutions to some of the most challenging medical and scientific problems.

For stakeholders, the key to success lies in leveraging technological advancements, fostering collaborations, and addressing ethical challenges. With sustained investment and innovation, epigenetics is poised to become a cornerstone of modern medicine.

[didanawisgi]

Abstract

The relentless, protracted evolution of the SARS-CoV-2 virus imposes tremendous pressure on herd immunity and demands versatile adaptations by the human host genome to counter transcriptomic and epitranscriptomic alterations associated with a wide range of short- and long-term manifestations during acute infection and post-acute recovery, respectively. To promote viral replication during active infection and viral persistence, the SARS-CoV-2 envelope protein regulates host cell microenvironment including pH and ion concentrations to maintain a high oxidative environment that supports template switching, causing extensive mitochondrial damage and activation of pro-inflammatory cytokine signaling cascades. Oxidative stress and mitochondrial distress induce dynamic changes to both the host and viral RNA m6A methylome, and can trigger the derepression of long interspersed nuclear element 1 (LINE1), resulting in global hypomethylation, epigenetic changes, and genomic instability. The timely application of melatonin during early infection enhances host innate antiviral immune responses by preventing the formation of “viral factories” by nucleocapsid liquid-liquid phase separation that effectively blockades viral genome transcription and packaging, the disassembly of stress granules, and the sequestration of DEAD-box RNA helicases, including DDX3X, vital to immune signaling. Melatonin prevents membrane depolarization and protects cristae morphology to suppress glycolysis via antioxidant-dependent and -independent mechanisms. By restraining the derepression of LINE1 via multifaceted strategies, and maintaining the balance in m6A RNA modifications, melatonin could be the quintessential ancient molecule that significantly influences the outcome of the constant struggle between virus and host to gain transcriptomic and epitranscriptomic dominance over the host genome during acute infection and PASC.

[tumimmtxpapers]

Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity

An analogous field to epigenetics is referred to as epitranscriptomics, which focuses on the study of post-transcriptional chemical modifications in RNA. RNA molecules, including mRNA, tRNA, rRNA, and other non-coding RNA molecules, can be edited with numerous modifications. The most prevalent modification in eukaryotic mRNA is N6-methyladenosine (m⁶A), which is a reversible modification found in over 7000 human genes. Recent technological advances have accelerated the characterization of these... http://dlvr.it/T0MYFV

[bbygirl-aemond]

Hi! I just saw your posts about the hair colors of Targaryen children and now i'm very curious, have you ever done a similar analysis on Ned and Catelyn's children and why 4 out of 5 of them had auburn hair and blue eyes, both being (very) recessive traits? I remember reading somewhere that Rickard and Lyarra Stark were first cousins, both trueborn Starks who bore four long-faced, grey-eyed brunetes, so i think that its safe to say that Ned had BB genes; meanwhile, we don't really know anything about Minisa Whent, but since Cat and both of her siblings were born blue-eyed gingers, they all probably had bb genothypes. So, technically, a Ned/Cat pairing should result in all Bb children, isn't it? How come most of those babes inherited their mother's coloring, then?

ooh yes this is so interesting! so my original post here only talked about one gene, so that i could use mendelian genetics and punnett squares and everything: the gene for the protein eumelanin, which is the pigment that makes brown hair. this let me treat inheritance like it only involved two possible versions of one gene for the trait of hair color, one dominant and one recessive. if you don't meet these requirements, you can't use the punnett square probabilities to predict traits, since inheritance won't be that simplistic.

the pigment that makes hair reddish in color is actually an entirely separate chemical called pheomelanin, which is encoded by more than just two genes (it results from a polymorphic mutation in the original brown hair gene, but there are way more than two types of mutations that count so there are easily like 5+ versions of this gene). as a result, there's no simple dominant or recessive inheritance pattern here to follow the way there is when we're just talking about brown vs blond hair.

but for simplicity's sake, let's denote eumelanin with a B, and pheomelanin with an R. in the absence of either of these genes, hair will be blond. the more B's you have, the browner your hair will be, and the more R's you have, the redder your hair will be. the possibilities aren't either brown or red; it's a spectrum rather than a binary. and remember, each version of the R gene encodes a slightly different intensity and brightness of red hair, so we don't have enough information to even compare two R genes to each other since they'll likely affect hair color very differently.

we know that ned has two copies of the B gene, but we know nothing about if he has any R genes since the two copies of eumelanin will overpower everything else. we know that cat has no B genes because she's a tully, but has at least one copy and likely two copies of the R gene. so their kids will have:

no more than one copy of the B gene

0-2 copies of the R gene

but we know nothing about what types of R genes are involved here. we don't know which specific mutation it is. we don't know if it encodes really faint color or really intense color, and we don't know if it encodes light orange or dark orange. we also don't know how it interacts with the B genes; it won't be 100% dominant or 100% recessive, but we can't determine if it's more 90:10 or 20:80 or what. i will say that given cat's hair color is very much red and not faint in color, and given that ned can only pass down one B gene onto his kids, at the very least i expect every child to have hair that is much redder than their father. something like auburn, lol.

lastly, there are also epigenetic and epitranscriptomic factors that determine how much a gene is expressed. this adds a layer of complexity on top of whether or not the genes are inherited and how strong the genes are in and of themselves. and here, how much the B and R genes are expressed relative to each other will play a big part in where the kids fall on the brown to red hair spectrum.

as for the eye color, it's really not a shocker that the blue eyes would be dominant! i know we think of blue eyes as being encoded by recessive genes, but the inheritance patterns for eye color aren't super black and white. they have a lot to do with where pigment is expressed in the eye, not just how much. for example, both brown eyes and blue eyes have melanin in the back layer of the iris, but only brown eyes have melanin in the front layer.

grey eyes are actually the rarest eye color, even rarer than blue eyes, and they aren't necessarily dominant over blue eyes! they're not gray just because they lack that front layer of pigment, but because they also have higher levels of collagen in a particular part of their iris, causing the light to refract in a specific way. it's a different mechanism than the mechanism for blue eyes entirely, and it's not necessarily dominant. when a grey-eyed parent and a blue-eyed parent have children, they're usually almost all blue-eyed as a result.

tldr: red hair is a completely different and unique pattern of inheritance from brown hair! grey eyes are completely different from blue eyes in the same way. neither of these traits follow mendelian patterns of inheritance, and they also don't fit into neat dominant versus recessive categories, so this isn't a case where we can apply the statistics of things like punnett squares or dominant/recessive genes. it's very difficult to try to support the claim that it would be "unlikely" for ned and cat's kids to turn out this way as a result. hope this helps!

[jobrxiv]

Postdoc position in Bioinformatics - 3D chromatin architecture and non-codi The Italian Institute of Technology Are you Interested in #3D genome architecture #epigenetics and #ncRNAs? come join us at #IIT as a #postdoctoral bioinformatician! See the full job description on jobRxiv: https://jobrxiv.org/job/the-italian-institute-of-technology-27778-postdoc-position-in-bioinformatics-3d-chromatin-architecture-and-non-codi/?feed_id=43190 #ScienceJobs #hiring #research #bioinformatics #multi-omic #Genomics #3Dchromatin #epigenetics #epitranscriptomics Genova #Italy #Bioinformatician

[genefish]

New in Pubmed: A functional m6 A-RNA methylation pathway in the oyster Crassostrea gigas assumes epitranscriptomic regulation of lophotrochozoan development.

Related Articles

A functional m6 A-RNA methylation pathway in the oyster Crassostrea gigas assumes epitranscriptomic regulation of lophotrochozoan development.

FEBS J. 2020 Aug 02;:

Authors: Le Franc L, Bernay B, Petton B, Since M, Favrel P, Riviere G

Abstract N6 -methyladenosine (m6 A) is a prevalent epitranscriptomic mark in eukaryotic RNA, with crucial roles for mammalian and ecdysozoan development. Indeed, m6 A-RNA and the related protein machinery are important for splicing, translation, maternal-to-zygotic transition and cell differentiation. However, to date, the presence of an m6 A-RNA pathway remains unknown in more distant animals, questioning the evolution and significance of the epitranscriptomic regulation. Therefore, we investigated the m6 A-RNA pathway in the oyster Crassostrea gigas, a lophotrochozoan model whose development was demonstrated under strong epigenetic influence. Using mass spectrometry and dot blot assays, we demonstrated that m6 A-RNA is actually present in the oyster and displays variations throughout early oyster development, with the lowest levels at the end of cleavage. In parallel, by in silico analyses, we were able to characterize at the molecular level a complete and conserved putative m6 A-machinery. The expression levels of the identified putative m6 A writers, erasers and readers were strongly regulated across oyster development. Finally, RNA pull-down coupled to LC-MS/MS allowed us to prove the actual presence of readers able to bind m6 A-RNA and exhibiting specific developmental patterns. Altogether, our results demonstrate the conservation of a complete m6 A-RNA pathway in the oyster and strongly suggest its implication in early developmental processes including MZT. This first demonstration and characterization of an epitranscriptomic regulation in a lophotrochozoan model, potentially involved in the embryogenesis, brings new insights into our understanding of developmental epigenetic processes and their evolution.

PMID: 32743927 [PubMed - as supplied by publisher]

from pubmed: crassostrea gigas https://ift.tt/3kbVPPN via IFTTT

[healthcaremarketanalysis]

Exploring the Epigenetics Market: Trends, Growth, and Future Prospects

The epigenetics market is gaining significant momentum in the life sciences and healthcare sectors. This field, which studies heritable changes in gene expression without altering the DNA sequence, is instrumental in understanding complex biological processes and diseases. From drug discovery to personalized medicine, epigenetics offers transformative potential, making it a crucial area of research and development.

In this blog, we’ll delve into the key trends, market dynamics, applications, and growth drivers shaping the epigenetics market.

Understanding Epigenetics

Epigenetics refers to modifications on DNA or associated proteins that regulate gene activity without changing the underlying sequence. These modifications include:

DNA Methylation – The addition of methyl groups to DNA, often silencing gene expression.

Histone Modification – Changes in proteins around which DNA is wrapped, affecting gene accessibility.

Non-Coding RNAs – Molecules that influence gene expression post-transcriptionally.

Epigenetic mechanisms are reversible, making them attractive therapeutic targets for diseases like cancer, neurodegenerative disorders, and autoimmune conditions.

Market Overview

Market Size and Growth

The global epigenetics market was valued at approximately $1.4 billion in 2023 and is projected to grow at a CAGR of 15-18% over the next decade. This growth is driven by increasing research in gene therapy, rising cancer prevalence, and advancements in epigenetic technologies.

Key Market Segments

The market can be categorized into the following:

Products:

Reagents

Kits

Instruments (e.g., sequencers, microarrays)

Software

Applications:

Oncology

Developmental Biology

Metabolic Disorders

Neurology

End Users:

Academic Research Institutions

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Drivers of Market Growth

1. Rising Prevalence of Cancer

Cancer is a leading application area for epigenetic research. Abnormal epigenetic modifications are closely linked to tumorigenesis. Epigenetic therapies, such as DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors, are showing promising results in cancer treatment.

2. Advances in Epigenomics Technologies

The development of high-throughput sequencing and microarray platforms has made it possible to study epigenetic changes on a genome-wide scale. Tools like CRISPR-based epigenome editing are expanding research possibilities.

3. Increasing Focus on Personalized Medicine

Epigenetics plays a critical role in tailoring therapies based on individual genetic and epigenetic profiles. This approach is gaining traction, especially in oncology and chronic disease management.

4. Government and Private Funding

Governments worldwide are investing heavily in genomics and epigenetics research. For instance, the National Institutes of Health (NIH) in the U.S. allocates substantial grants for epigenetics projects. Private investments and collaborations are also fueling market growth.

Challenges in the Epigenetics Market

1. High Costs of Research and Equipment

Epigenetic research requires advanced instruments and reagents, which can be cost-prohibitive for smaller organizations.

2. Complexity of Epigenetic Mechanisms

The dynamic and reversible nature of epigenetic changes makes it challenging to pinpoint causal relationships between modifications and diseases.

3. Regulatory and Ethical Issues

Using epigenetic data in personalized medicine raises concerns about data privacy and ethical implications.

Emerging Trends in the Epigenetics Market

1. Integration of AI and Big Data

Artificial Intelligence (AI) and machine learning algorithms are being used to analyze complex epigenomic datasets, accelerating discoveries.

2. Focus on Epitranscriptomics

This subfield studies modifications in RNA rather than DNA, opening new avenues for understanding gene regulation.

3. Development of Epigenetic Biomarkers

Biomarkers are being developed for early diagnosis, prognosis, and treatment monitoring in diseases like cancer, Alzheimer’s, and diabetes.

4. Expansion of Non-Oncology Applications

While oncology dominates the market, epigenetics is increasingly applied in neurodegenerative diseases, cardiovascular disorders, and metabolic syndromes.

Competitive Landscape

Key players in the epigenetics market include:

Illumina, Inc. – Leading in sequencing technologies.

Thermo Fisher Scientific, Inc. – Offering comprehensive epigenetics solutions.

Abcam plc – Specializing in antibodies and kits for epigenetic research.

Qiagen – Providing tools for epigenomic studies.

Merck KGaA – Known for its advanced reagents and inhibitors.

Collaborations, acquisitions, and product launches are common strategies adopted by these players to strengthen their market position.

Applications of Epigenetics

1. Cancer Research and Therapy

Epigenetic drugs are used to reprogram cancer cells, making them more susceptible to traditional therapies.

2. Developmental Biology

Epigenetics helps unravel how environmental factors influence gene expression during development.

3. Neurology

Research in conditions like Alzheimer’s and Parkinson’s diseases focuses on epigenetic mechanisms underlying neuronal dysfunction.

4. Agriculture and Veterinary Science

Epigenetic studies in plants and animals aim to enhance productivity and disease resistance.

Future Prospects

The future of the epigenetics market is promising, with continued advancements in technology and an expanding scope of applications. Personalized medicine and precision oncology are expected to be major growth areas. Moreover, the rise of epigenome editing tools and novel biomarkers will drive innovation in diagnostics and therapeutics.

Conclusion

The epigenetics market represents a dynamic and rapidly evolving field with immense potential to transform healthcare and research. As we continue to uncover the intricacies of the epigenome, the applications of this science will expand, offering solutions to some of the most challenging medical and scientific problems.

For stakeholders, the key to success lies in leveraging technological advancements, fostering collaborations, and addressing ethical challenges. With sustained investment and innovation, epigenetics is poised to become a cornerstone of modern medicine.

[rnomics]

Epitranscriptomic profiling across cell types reveals associations between APOBEC1-mediated #RNA editing, gene expression outcomes, and cellular function [Systems Biology]

Epitranscriptomics refers to posttranscriptional alterations on an #mRNA sequence that are dynamic and reproducible, and affect gene expression in a similar way to epigenetic modifications. However, the functional relevance of those modifications for the transcript, the cell, and the organism remain poorly understood. Here, we focus on #RNA editing and... http://bit.ly/2jPjOdd #PNAS

[biotechtimes]

IIT Hyderabad PhD Admissions – July 2020

New Post has been published on https://biotechtimes.org/2020/03/27/iit-hyderabad-phd-admissions-july-2020/

IIT Hyderabad PhD Admissions – July 2020

IIT Hyderabad PhD Admissions

Indian Institute of Technology (IIT) Hyderabad has announced official notification for the PhD program at the Department of Biotechnology. IIT Hyderabad PhD Admissions 2020. Eligible and interested candidates are requested to check out the below-mentioned details:

Indian Institute of Technology Hyderabad Department of Biotechnology PhD Admissions July 2020

The department of Biotechnology has faculty members with cutting-edge research expertise in areas encompassing both applied and basic research:

NMR spectroscopy, X-ray crystallography, Computational biology, Neurodegenerative diseases, Ion channel physiology, Protein misfolding diseases, Infectious diseases, HIV biology, Cancer biology, DNA repair, Molecular mechanisms of diseases using zebrafish animal model, High-resolution imaging, Molecular & cellular neurosciences, RNA molecular biology, Genomics and Epitranscriptomics, Drug design and Enzyme Engineering.

Research activities in the department are funded by national agencies such as DBT, DST, ICMR, CSIR, etc.

Two postgraduate degree programs are offered currently: MTech in Medical Biotechnology & Ph.D. in Biotechnology.

The mission of the Ph.D. program at the department is to provide research training that begets leaders in academia, biotechnology and beyond; leaders that can shape the science of the future.

Applications are invited from suitably qualified and motivated candidates for admission to the Ph.D. program at Department of Biotechnology, IITH in the following research area:

Research Area Faculty Membrane protein dynamics in breast cancer, drug discovery using animal models Dr. Anamika Bhargava DNA repair Dr. Anindya Roy Cancer Genomics and biomarker discovery, RNA Biology, Protein Engineering, Epitranscriptomics, Computational biology and data mining Dr. Ashish Misra (***) Molecular mechanism of Amyotrophic Lateral Sclerosis (ALS) disease. Protein misfolding diseases. Yeast S. cerevisiae genetics. Neurodegenerative diseases, Alzheimer’s disease, Huntington’s disease. Renal amyloidosis. Dr. Basant K Patel DNA-Protein and protein-protein interaction in the innate immune response to cancer and viral infection. Dr. N K Raghavendra Epigenetics, Enzyme engineering, Structure-based drug design, Structural Biology, X-ray crystallography, Biophysics & Biochemistry, Computational biology, Characterization of cancer drug targets Dr. Rajakumara Eerappa (###) Microbial genomics, Antimicrobial resistance, Antigen/protein interaction, Protein…protein interaction, Rational antibiotic design, Biomolecular NMR, Molecular dynamics simulation Dr T. Rathinavelan

Minimum Eligibility Criteria

M.Tech or any equivalent degree in any allied area of Life Sciences.

MSc degree in any allied area of Life Sciences and possessing a GATE score or valid National level JRF qualification.

Bachelor’s degree in Engineering /Technology and possessing a valid GATE score.

Candidates with valid CSIR-JRF / UGC-JRF/ DBT-JRF award or any other equivalent national level qualification for research fellowship (eg. DST-INSPIRE fellowship) are encouraged to apply.

Candidates should also possess:

General category: at least 63% marks in the highest qualifying degree

OBC category: at least 62% marks in the highest qualifying degree

SC/ST category: at least 60% marks in the highest qualifying degree

For those who have not yet completed their qualifying examination, the marks obtained up to 3 rd semester for MSc/Mtech and 7 th semester for B. Tech Students will be considered.

(***): Candidates with experience/interest in computational biology and data mining are encouraged to apply.

(###): Candidates with experience/interest in Machine or Deep learning and molecular modeling and prediction are encouraged to apply.

Notes: 1) Ensure that the minimum eligibility criteria is met before applying. The department reserves the right to set any cut off criteria for shortlisting the candidates.

Selection procedure

1) Candidates will be shortlisted according to the criteria set by a shortlisting committee.

2) Only shortlisted candidates will be called for an interview to be held at IIT Hyderabad.

3) The selection to the Ph.D. program will be based on the performance in the interview.

4) Request to change the interview date/time will not be entertained.

How to apply

Interested candidates can apply online through IIT Hyderabad’s website: http://www.iith.ac.in

For any further information, please contact by email: phd_biotech@iith.ac.in

Note:

The department has the right not to select any candidate if appropriate candidates are not found.

Hostel facility may not be available immediately to the admitted candidates, but, may eventually be available.

Download Brochure